The ASCO 2020 Virtual Scientific Program (May 29-31) provided the opportunity to connect with oncology professionals around the world to explore and discuss cutting-edge research, therapies, and state-of-the-art treatment modalities that are changing the future of cancer care.
Journal of Clinical Pathways provided coverage of the most relevant and important sessions of the meeting.
A cross-sectional survey showed that, while many oncology providers believe biosimilar products to be safe and effective, they may be hesitant to prescribe these products for multiple reasons.
Results of a large post-hoc analysis showed that preexisting or venetoclax-induced neutropenia can be effectively managed in patients with relapsed or refractory CLL.
Simulation modeling demonstrated that chemotherapy-induced febrile neutropenia prophylaxis with a supportive care biosimilar can lead to significant cost savings.
The longest safety and efficacy follow-up to data for a recently approved BTK inhibitor for treatment-naïve, relapsed or refractory CLL shows durable responses with no new long-term safety issues.
A study that tracked average reimbursement by CMS for a supportive care biosimilar may have a significant impact on an OCM practice’s performance.
A retrospective study presented by the North American MCL Consortium provides clinical and biologic characteristics that are relevant to the prognosis of patients with MCL.
A multicenter study of MRD-driven time-limited combination therapy for patients with CLL demonstrated rapid undetectable minimal residual disease.
When performed in a timely manner, next-generation sequencing can impact therapy decisions in more than 30% of patients with AML.
A protocol-specific final analysis of the KEYNOTE-100 study offered further insight into optimal treatment of patients with recurrent advanced ovarian cancer, especially in those with PD-L1 expression.
Kirsten M Timms, Myriad Genetic Laboratories, Inc, and colleagues designed an analysis to determine whether genomic instability scores and HRD testing produce comparable results in predicting PARP inhibitor response for patients with ovarian cancer.
Huntsman Cancer Institute’s hospital-at-home program demonstrated improved patient outcomes, including reduced hospitalizations and decreased ED visits.
Helen MacKay, MBChB, BSc, MRCP, MD, highlighted the results of an updated randomized study that was the first to show a median overall survival benefit from surgery in women with recurrent platinum-sensitive ovarian cancer.
Stewart B Fleishman, MD, offered a commentary on the noteworthy studies being presented at the meeting on health services research and quality improvement.
Autumn J McRee, MD, associate professor of medicine, The University of North Carolina at Chapel Hill, highlighted three clinical trials of practice-changing potential in metastatic colorectal cancer.
Electronic patient-reported outcome assessment provides an effective and feasible approach for recording symptoms and quality of life in patients participating in prostate cancer clinical trials.
Aurora Health Care’s use of evidence-based clinical pathways led to significant cost savings for patients with NSCLC as well as a significant rise in clinical trial entry.
Dana-Farber Cancer Institute reports concordance results following implementation of their web-based oncology pathways program.
A study characterized practice patterns and survival outcomes in older patients with mantle cell lymphoma as well as predictive factors of survival after targeted therapy and autologous transplantation.
A chemotherapy-based combination regimen may be safe and effective in the frontline setting for older patients with AML, according to long-term data.
While bone marrow biopsies are used to confirm complete response in clinical trial patients with lymphoma, researchers sought to examine their value in light of their potential negative impact on patient participation.
A study compared health care resource utilization and costs of multiple regimens in patients with relapsed or refractory mantle cell lymphoma.
An integrated palliative and oncology care model for patients with AML receiving intensive chemotherapy may lead to improved patient QoL, psychological distress, and end-of-life care, according to a new study.
In patients with relapsed or refractory classic Hodgkin lymphoma, an anti-PD-1 therapy should be considered standard of care.